- Japan’s Eisai Co. develops new drug for Alzheimer disease.
- The drug has been developed with U.S. firm Biogen Inc.
- The U.S. Food and Drug Administration on Monday approved of the new drug named ‘Aduhelm’.
- Aduhelm reduces amyloid beta proteins in the brain.
On Wednesday, Japan’s Eisai Co. CEO Haruo Naito announced that they have developed a new drug for Alzheimer’s disease with U.S. firm Biogen Inc. The drug is said to have the potential to become a “blockbuster” product.
According to reports, the U.S. Food and Drug Administration on Monday approval the new drug name “Aduhelm” raising hopes for the treatment of Alzheimer’s disease. However, concern remains about higher medical costs as a patient would be charged $56,000 a year.
Naito mentioned that the pricing of the drug should reflect multiple factors, such as the impact on the families of patients taking it.
According to the drug making company, Aduhelm reduces amyloid beta proteins in the brain, which are believed to play a key role in causing Alzheimer’s disease.
Biogen, headquartered in Cambridge, Massachusetts mentioned that the drug will be administered as an infusion once every four weeks at a yearly cost of $56,000.
The drug will be used by one to two million patients in the United States and about one million in Japan.
Biogen Japan Ltd. submitted its application for approval with the country’s health ministry in December. The ministry on Tuesday mentioned that it may decide whether to allow its domestic use by the end of this year.
According to Eisai, they have also developed the drug “Aricept” for the treatment of Alzheimer’s disease. Aduhelm is the first new therapy for the disease approved by the FDA in nearly two decades.